Atara Biotherapeutics Faces Class Action Lawsuit Over Regulatory Issues
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy ATRA?
Source: Globenewswire
- Class Action Initiated: The Portnoy Law Firm has filed a class action against Atara Biotherapeutics on behalf of investors who purchased securities between May 20, 2024, and January 9, 2026, with a deadline for lead plaintiff motions set for May 22, 2026, indicating increased legal risks for the company.
- Regulatory Scrutiny Risks: Atara faces significant risks of FDA non-approval for its tabelecleucel BLA due to manufacturing issues and deficiencies in the ALLELE study, which could lead to a substantial negative impact on the company's financial condition and investor confidence.
- Stock Price Volatility: Following the receipt of a Complete Response Letter (CRL) on January 16, 2025, Atara's stock plummeted from $13.16 to $7.83, a decline of 40.5%, reflecting market pessimism regarding the company's future prospects.
- Clinical Trials Halted: The FDA placed a clinical hold on Atara's IND applications due to unresolved GMP compliance issues, resulting in an 8% drop in stock price, highlighting the company's significant challenges in regulatory compliance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ATRA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ATRA
Wall Street analysts forecast ATRA stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 5.150
Low
18.00
Averages
21.50
High
25.00
Current: 5.150
Low
18.00
Averages
21.50
High
25.00
About ATRA
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219, and ATA3431. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 allogeneic CD19 CAR T immunotherapy, targeting B-cell malignancies and autoimmune diseases, is based on a next-generation 1XX CAR co-stimulatory domain and EBV T-cell platform and does not require TCR or HLA gene editing. ATA3431 is an allogeneic, bispecific CAR directed against CD19 and CD20 for B-cell malignancies and autoimmune disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Reminder of Class Action Lawsuit for Atara Biotherapeutics Securities
- Class Action Notification: Rosen Law Firm reminds investors who purchased Atara Biotherapeutics (NASDAQ: ATRA) securities between May 20, 2024, and January 9, 2026, that they must apply to be lead plaintiff by May 22, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that Atara made false or misleading statements during this period, failing to disclose manufacturing issues and clinical trial risks, which led to investor losses when the true situation became known, negatively impacting the company's financial condition.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked No. 1 by ISS Securities Class Action Services in 2017, demonstrating its expertise and successful track record in this field.
- Participation Instructions: Investors can visit the Rosen Law Firm website or call the toll-free number for more information, ensuring they select qualified legal counsel to protect their rights in the litigation and avoid inexperienced intermediary firms.
See More
Class Action Lawsuits Filed for Multiple Companies
- Lufax Shareholder Lawsuit: Shareholders of Lufax Holding Ltd. have filed a class action due to the company's failure to disclose inadequate internal controls and misstated financial results during the period from April 7, 2023, to January 26, 2025, with a lead plaintiff deadline of May 20, 2026.
- Atara Biotherapeutics Lawsuit: Atara Biotherapeutics, Inc. shareholders initiated a lawsuit for the period from May 20, 2024, to January 9, 2026, alleging undisclosed manufacturing issues and clinical trial risks that jeopardized FDA approval prospects, with a lead plaintiff deadline of May 22, 2026.
- Coty Shareholder Class Action: Coty Inc. shareholders have filed a class action due to the company's failure to disclose underperformance in its Consumer Beauty segment and slowing market growth from November 5, 2025, to February 4, 2026, with a lead plaintiff deadline of May 22, 2026.
- Legal Consultation Information: The Law Offices of Frank R. Cruz remind investors who suffered losses during these periods to contact them for legal advice to protect their rights and interests.
See More
Notice of Class Action Lawsuit Against Atara Biotherapeutics Securities
- Class Action Notice: Rosen Law Firm reminds investors who purchased Atara Biotherapeutics securities between May 20, 2024, and January 9, 2026, that they must apply to be lead plaintiff by May 22, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that Atara made false and misleading statements during the class period, failing to disclose manufacturing issues and clinical trial risks, which led to significant financial losses for investors and impacted the company's reputation and market confidence.
- Law Firm Advantages: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, demonstrating its success and resources in this field, urging investors to choose experienced legal counsel wisely.
- Investor Action Recommendations: Investors can visit the Rosen Law Firm website or call the toll-free number for more information on how to participate in the lawsuit, ensuring they receive the necessary legal support and potential compensation in the class action.
See More
Atara Biotherapeutics Faces Class Action Lawsuit
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Atara Biotherapeutics in the Central District of California, representing investors who purchased Atara securities between May 20, 2024, and January 9, 2026, seeking damages for violations of federal securities laws, indicating a significant increase in legal risks for the company.
- Regulatory Pressure from FDA: On January 16, 2025, Atara received a Complete Response Letter from the FDA indicating that its Biologics License Application for tabelecleucel was not approved, resulting in a 40.5% drop in stock price, reflecting the direct impact of regulatory hurdles on the company's financial condition.
- Clinical Trials Halted: Due to GMP compliance issues identified during inspections of a third-party manufacturing facility, the FDA placed a clinical hold on Atara's Investigational New Drug applications, exacerbating market concerns about its product development prospects and causing a further 7.91% decline in stock price.
- Investor Confidence Shaken: On January 12, 2026, Atara received another Complete Response Letter from the FDA stating that its tabelecleucel application did not meet the effectiveness criteria for accelerated approval, leading to a 56.99% drop in stock price, demonstrating a severe erosion of investor confidence in the company's future prospects.
See More
Atara Biotherapeutics Shareholder Notice Issued by Gross Law Firm
- Lawsuit Notice Issued: The Gross Law Firm has issued a notice to shareholders of Atara Biotherapeutics, encouraging those who purchased ATRA shares between May 20, 2024, and January 9, 2026, to contact the firm regarding potential lead plaintiff appointment, indicating significant legal risks for the company.
- Allegations Overview: The lawsuit alleges that Atara made materially false and misleading statements during the class period, failing to disclose manufacturing issues and deficiencies in the ALLELE study, which overstated the likelihood of FDA approval for tabelecleucel and could have a significant negative impact on the company's financial condition.
- Increased Regulatory Risks: The manufacturing issues have subjected Atara to heightened regulatory scrutiny, which not only jeopardizes ongoing clinical trials but may also lead to a decline in investor confidence, adversely affecting stock performance.
- Shareholder Action Recommendations: Shareholders are advised to register for the class action by May 22, 2026, and will receive real-time updates on the case's progress, reflecting the company's commitment to protecting shareholder rights.
See More
Atara Biotherapeutics Class Action Reminder
- FDA Response Letter Impact: On January 16, 2025, Atara received a Complete Response Letter from the FDA regarding its EBVALLO treatment, causing a stock price drop of $5.33, or 40.5%, severely harming investor interests.
- Clinical Hold Imposed: On January 21, 2025, Atara disclosed that the FDA placed a clinical hold on its IND applications due to GMP compliance issues, leading to a further stock price decline of $0.52, or 7.9%, exacerbating investor losses.
- Second Response Letter: On January 12, 2026, Atara received another CRL from the FDA indicating that its resubmitted EBVALLO application could not be approved, resulting in a stock price drop of $7.79, or 56.99%, highlighting increasing regulatory risks for the company.
- Class Action Context: The class action lawsuit alleges that Atara failed to disclose critical manufacturing issues and clinical trial deficiencies throughout the class period, leading to investor misconceptions about the company's prospects, which could significantly impact its financial condition.
See More
Reminder of Class Action Lawsuit for Atara Biotherapeutics Securities
- Class Action Notification: Rosen Law Firm reminds investors who purchased Atara Biotherapeutics (NASDAQ: ATRA) securities between May 20, 2024, and January 9, 2026, that they must apply to be lead plaintiff by May 22, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that Atara made false or misleading statements during this period, failing to disclose manufacturing issues and clinical trial risks, which led to investor losses when the true situation became known, negatively impacting the company's financial condition.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked No. 1 by ISS Securities Class Action Services in 2017, demonstrating its expertise and successful track record in this field.
- Participation Instructions: Investors can visit the Rosen Law Firm website or call the toll-free number for more information, ensuring they select qualified legal counsel to protect their rights in the litigation and avoid inexperienced intermediary firms.
See More
Class Action Lawsuits Filed for Multiple Companies
- Lufax Shareholder Lawsuit: Shareholders of Lufax Holding Ltd. have filed a class action due to the company's failure to disclose inadequate internal controls and misstated financial results during the period from April 7, 2023, to January 26, 2025, with a lead plaintiff deadline of May 20, 2026.
- Atara Biotherapeutics Lawsuit: Atara Biotherapeutics, Inc. shareholders initiated a lawsuit for the period from May 20, 2024, to January 9, 2026, alleging undisclosed manufacturing issues and clinical trial risks that jeopardized FDA approval prospects, with a lead plaintiff deadline of May 22, 2026.
- Coty Shareholder Class Action: Coty Inc. shareholders have filed a class action due to the company's failure to disclose underperformance in its Consumer Beauty segment and slowing market growth from November 5, 2025, to February 4, 2026, with a lead plaintiff deadline of May 22, 2026.
- Legal Consultation Information: The Law Offices of Frank R. Cruz remind investors who suffered losses during these periods to contact them for legal advice to protect their rights and interests.
See More
Notice of Class Action Lawsuit Against Atara Biotherapeutics Securities
- Class Action Notice: Rosen Law Firm reminds investors who purchased Atara Biotherapeutics securities between May 20, 2024, and January 9, 2026, that they must apply to be lead plaintiff by May 22, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that Atara made false and misleading statements during the class period, failing to disclose manufacturing issues and clinical trial risks, which led to significant financial losses for investors and impacted the company's reputation and market confidence.
- Law Firm Advantages: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, demonstrating its success and resources in this field, urging investors to choose experienced legal counsel wisely.
- Investor Action Recommendations: Investors can visit the Rosen Law Firm website or call the toll-free number for more information on how to participate in the lawsuit, ensuring they receive the necessary legal support and potential compensation in the class action.
See More
Atara Biotherapeutics Faces Class Action Lawsuit
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Atara Biotherapeutics in the Central District of California, representing investors who purchased Atara securities between May 20, 2024, and January 9, 2026, seeking damages for violations of federal securities laws, indicating a significant increase in legal risks for the company.
- Regulatory Pressure from FDA: On January 16, 2025, Atara received a Complete Response Letter from the FDA indicating that its Biologics License Application for tabelecleucel was not approved, resulting in a 40.5% drop in stock price, reflecting the direct impact of regulatory hurdles on the company's financial condition.
- Clinical Trials Halted: Due to GMP compliance issues identified during inspections of a third-party manufacturing facility, the FDA placed a clinical hold on Atara's Investigational New Drug applications, exacerbating market concerns about its product development prospects and causing a further 7.91% decline in stock price.
- Investor Confidence Shaken: On January 12, 2026, Atara received another Complete Response Letter from the FDA stating that its tabelecleucel application did not meet the effectiveness criteria for accelerated approval, leading to a 56.99% drop in stock price, demonstrating a severe erosion of investor confidence in the company's future prospects.
See More
Atara Biotherapeutics Shareholder Notice Issued by Gross Law Firm
- Lawsuit Notice Issued: The Gross Law Firm has issued a notice to shareholders of Atara Biotherapeutics, encouraging those who purchased ATRA shares between May 20, 2024, and January 9, 2026, to contact the firm regarding potential lead plaintiff appointment, indicating significant legal risks for the company.
- Allegations Overview: The lawsuit alleges that Atara made materially false and misleading statements during the class period, failing to disclose manufacturing issues and deficiencies in the ALLELE study, which overstated the likelihood of FDA approval for tabelecleucel and could have a significant negative impact on the company's financial condition.
- Increased Regulatory Risks: The manufacturing issues have subjected Atara to heightened regulatory scrutiny, which not only jeopardizes ongoing clinical trials but may also lead to a decline in investor confidence, adversely affecting stock performance.
- Shareholder Action Recommendations: Shareholders are advised to register for the class action by May 22, 2026, and will receive real-time updates on the case's progress, reflecting the company's commitment to protecting shareholder rights.
See More
Atara Biotherapeutics Class Action Reminder
- FDA Response Letter Impact: On January 16, 2025, Atara received a Complete Response Letter from the FDA regarding its EBVALLO treatment, causing a stock price drop of $5.33, or 40.5%, severely harming investor interests.
- Clinical Hold Imposed: On January 21, 2025, Atara disclosed that the FDA placed a clinical hold on its IND applications due to GMP compliance issues, leading to a further stock price decline of $0.52, or 7.9%, exacerbating investor losses.
- Second Response Letter: On January 12, 2026, Atara received another CRL from the FDA indicating that its resubmitted EBVALLO application could not be approved, resulting in a stock price drop of $7.79, or 56.99%, highlighting increasing regulatory risks for the company.
- Class Action Context: The class action lawsuit alleges that Atara failed to disclose critical manufacturing issues and clinical trial deficiencies throughout the class period, leading to investor misconceptions about the company's prospects, which could significantly impact its financial condition.
See More
